

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHANCETON FINANCIAL GROUP LIMITED

川盟金融集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8020)

THE ESTABLISHMENT OF THE MEDICAL COMMITTEE

Reference is made to the announcements of Chanceton Financial Group Limited (the “**Company**”) dated 24 August 2013, 9 May 2013, 8 July 2013 (the “**Announcements**”). Unless otherwise stated, capitalized items herein would have the same meanings as those in the Announcements.

The Board of directors of the Company (the “**Board**”) is pleased to announce that Century Health Pharmaceutical Limited (“**Century Health Pharmaceutical**”), a wholly-owned subsidiary of the Company has established a medical committee (the “**Medical Committee**”) with effect on 17 October 2013.

INTRODUCTION OF THE MEDICAL COMMITTEE

On 5 December 2012, Mysteriously Time Investments Limited, a wholly-owned subsidiary of the Company completed the acquisition of 20% of Revenue Synthesis Limited, which indirectly owns 100% of Beijing Century Health (the “**20% Acquisition**”), signaling the start of the first direct investment by the Group and its involvement in the medical and pharmaceutical industry. On 13 June 2013, the Group further increased its shareholding in Revenue Synthesis Limited by acquiring and subscribing approximately 5% of its enlarged share capital (with the 20% Acquisition collectively called the “**AIDS Medication Business Acquisition**”).

Following the AIDS Medication Business Acquisition, on 8 July 2013, the Company, Revenue Synthesis and Beijing Century Health entered into an Exclusive Agreement to grant the Company worldwide exclusive right for 3 years from the signing of the Exclusive Agreement, to act as either distributor or management consultant for the marketing, distribution and sale of the health supplement, AIDS Medication Capsule and other related medical and pharmaceutical products and, in return, the Company will resell the Products as distributor or Revenue Synthesis Group shall pay the Company a management fee at a rate to be fixed by Formal Agreements as management consultant.

Beijing Century Health is principally engaged in research and development (“**R&D**”) of the AIDS Medication Capsule, as well as related medicines and pharmaceutical products in China, and owns the patent of the AIDS Medication Capsule. In addition to the AIDS Medication Capsule, Century Health is also developing health supplement products derived from its research on the AIDS Medication Capsule which can be commercialized and expand its business into the health supplement market.

With an aim of strengthening the relationship with Revenue Synthesis Group and leveraging on the expertise and network of the Revenue Synthesis Group, including Beijing Century Health, in the medical and pharmaceutical industry, the Board has decided to establish the Medical Committee. The Medical Committee, composed of reputable medical and pharmaceutical experts around the globe introduced by Revenue Synthesis Group, is to enhance and promote the Group’s R&D, investment and business development which are related to medication, prevention and/or control of AIDS (“**Chanceton AIDS Medication Business**”) and to further strengthen the medical and pharmaceutical professional team of the Group. In addition, the Medical Committee is also responsible for introducing investors and investment opportunities in relation to the AIDS medications and therapies to the Group.

Duties and responsibilities of the member of the Medical Committee

The duties and responsibilities of the members of the Medical Committee include, among others:

1. providing professional advice and consultation to Chanceton AIDS Medication Business;
2. assisting in the promotion of Chanceton AIDS Medication Business so as to expand the target customer group;
3. introducing strategic investors to the Group and promoting investment opportunities of the Group to potential investors;
4. providing the up to date information of the medicine and therapies which are related to AIDS medication, prevention and/or control of AIDS to the Group;
5. providing consultation to the Group on any upcoming projects or investment opportunities which is related to Chanceton AIDS Medication Business.

THE COMPOSITION OF THE MEDICAL COMMITTEE

The Board is pleased to announce that three reputable medical and pharmaceutical experts in the PRC, namely Academician Zeng Yi (“**Academician Zeng**”), Professor Li Zelin (“**Professor Li**”) and Professor Liu Shuwen (“**Professor Liu**”) respectively have been invited to the Medical Committee as the committee members. The biographies of Academician Zeng, Professor Li and Professor Liu are as follows:

Academician Zeng Yi

Academician Zeng is the father of Mr. Tsang Yan, an executive Director of the Company.

Academician Zeng graduated from Shanghai First Medical College in 1952 and is currently a Doctor and Postdoctoral Supervisor. He used to work as research fellow in MRC Virology Centre in Glasgow UK from 1974 to 1975 and his main concern was cancer basic research. He worked as research fellow in France National Research Centre from 1986 to 1987 and studied on HIV. He is a virologist, an Academician of Chinese Academy of Sciences, a foreign member of France National Academy of Medical Sciences and Russian Academy of Medical Sciences. He is regarded as the pioneer of the medical research of oncogenic virus and AIDS in China.

He used to be the director of Institute for Virology, the president of Chinese Academy of Preventive Medicine, a member of the third session of Academic Degrees Committee of the State Council and World Health Organization (“WHO”) Global Advisory Committee and a member of Executive Board of International Union of Microbiology, the president of Chinese Foundation for Prevention of STD and AIDS, the president of Chinese Preventive Medicine Association, an executive member of Chinese Medical Association, a member of WHO Expert Advisory Panel on Cancer and a member of steering committee of the United Nations Asia Pacific Leadership Forum on HIV/AIDS and Development.

Currently, he is the dean of College of Life Science and Bioengineering in Beijing University of Technology, a Doctor and Postdoctoral Supervisor, the chief scientist of National Center for AIDS/STD Control and Prevention, the director of Academician’s Laboratory in Institute for Viral Disease Control and Prevention of Chinese Center for Disease Control and Prevention. He is the honor president of Chinese Preventive Medicine Association and a professor of Institute of Human Virology of University of Maryland. He is a senior consultant of National Accreditation Board and director of Bio-safety Specialized Committee, an executive member of the Global Virus Network Center Science Leadership Council and director of China Global Virus Network Center.

Academician Zeng has more than 500 papers, 6 books and 4 collected papers published in Chinese and English. He has been awarded the title of National Outstanding Contribution Young and Middle-Aged. He has been awarded more than 20 national-level and ministry-level scientific and technological achievements, Tan Kah Kee Medical Science Award, Special Government Allowance and 2006 Barry & Martin's Prize, the title of National Prominent Contribution Young and Middle-Aged. In 2008, he was given Contribution Award on Public Health and Prevention Science Development of China Preventive Medicine Association. In 2012, he was awarded the Lifetime Achievement Award for Public Health from University of Maryland Institute of Human Virology.

Profession Li Zelin

Professor Li is the mother of Mr. Tsang Yan, an executive Director of the Company.

Professor Li graduated from School of Pharmacy, Shanghai First Medical College in 1953. She is currently a professor of Beijing University of Technology, the director of Virology and Pharmacology Laboratory of College of Life Science and Bioengineering in Beijing University of Technology. She was the director of Pharmacology Laboratory of the Institute for Material Medicine of China Academy of Traditional Chinese Medicine. She has over 40 years' working experience.

Professor Li mainly engages in the research of Chinese medicine for anti-virus, anti-bacteria and anti-parasites. In early 1970s, she started to join the research of anti-malaria drug-Qinghaosu supported by National People's Congress of the PRC. She was sent to University of London in 1980 as the first WHO visiting scholar of National Qinghaosu Cooperative Group. After she returned to China, she participated in the organization and instruction work of the national research of Qinghaosu.

She was the first major researcher approved for Qinghaosu Suppository and one of the eight main researchers of Qinghaohuzhi, a new drug approved in 1987. She was awarded the certificate and badge of National Third-Class Invention Award.

Since 1987, Professor Li has been working with Professor Zeng in the anti-HIV drug research to take the lead to establish an anti-HIV cell culture and drug screening method in China's first P3 laboratory. After screening over 300 hundred traditional Chinese medicines, she found about 30 samples which could inhibit the replication of HIV-1 according to the principle of Chinese traditional medicine, she selected several herbs to make a prescription named "ZL-1 Capsules", the study of which was later conducted in laboratories in Germany, France and US. Subsequent to the preclinical study, ZL-1 was approved by SFDA in 2008 for clinical trial. Since 2010, the clinical IIa stage has been completed and now IIb stage has commenced. She has built an anti-HIV drug research platform in Beijing University of Technology. In the past ten years, she has worked out a new series of compounds acting on new and multiple targets.

She obtained Qinghaosu National Second-Class Invention Award (a collective award, as a main pharmacology researcher), Qinghaohuzhi National Third-Class Invention Award (as one of the eight main researchers) and 5 provincial and ministry-level awards. She is entitled to Special Government Allowance. She has published 106 papers and has obtained 25 patents. In addition, she has been to nearly 20 countries to participate in international seminars, lectures and scientific and technological cooperation, and negotiations on scientific and technological cooperation.

Professor Liu Shuwen

Professor Liu got his doctoral degree in pharmacology in 2002 from the First Military Medical University. He studied in the US and was Assistant Member at LFK Research institute of New York Blood Center.

Professor Liu is a professor, doctoral supervisor, the dean of School of Pharmaceutical Sciences, Southern Medical University, and the director of Guangdong Key Laboratory of Drug Screening. Professor Liu is named as “Pearl River Scholar” by Guangdong Province and new century excellent talent by Ministry of Education.

Currently, Professor Liu is a director of Chinese Pharmacological Society, a vice-Chairman of Division of Anti-inflammatory and Immunological Pharmacology of Chinese Pharmacological Society, a vice-chairman of Guangdong Phamacological Society, and a member of Guangdong Discipline Review Committee. Professor Liu mainly engages in antiviral drug research to treat viral infectious diseases such as AIDS, influenza, etc. He was the first to report the fusion mechanism of SARS coronavirus and anti-SARS peptide. During recent years, Professor Liu has been awarded more than 10 grants such as National Major Scientific and Technological Project, Natural Science Foundation of China-Guangdong Collaborative Fund Key Project. He has obtained 7 national invention patents and applied 2 international PCT patents. Professor Liu was also awarded a second prize for Guangdong Scientific and Technological Advancement as the first author.

Professor Liu has already published more than 80 SCI papers in academic journals like Lancet, Journal of Biological Chemistry, Journal of AIDS, etc., with a total impact factor over 320, which were cited more than 1,500 times. Professor Liu’s personal h-index is 23. He was involved in the development of several new drugs, three of which have been granted new drug certificates by China Food and Drug Administration.

INFORMATION OF CENTURY HEALTH PHARMACEUTICAL AND REASON FOR THE ESTABLISHMENT OF THE MEDICAL COMMITTEE

Century Health Pharmaceutical is a company incorporating in Hong Kong with limited liability on 5 July 2013 which is indirectly wholly-owned by the Company.

As stated in the 2013 annual report of the Group, the Board considers exploring further corporate opportunities in, among others, the medical and pharmaceutical industry to expand its business scopes with a view to leverage on the expertise and network in the medical and pharmaceutical industry of Revenue Synthesis Group.

Following the entering into of the Exclusive Agreement on 8 July 2013, the Board is of the view that it is an opportunity for the Group to further bolster the collaboration with the Revenue Synthesis Group so as to leverage on the abundant resources of the Revenue Synthesis Group, including Beijing Century Health, in the medical and pharmaceutical industry for the development of the Group's AIDS Medication Business. In order to explore further investment and cooperation opportunities and diversify the business risk of the business activities of the Group, the establishment of the Medical Committee is able to enhance and promote Chanceton AIDS Medication Business through the introduction of worldwide reputable AIDS medical and pharmaceutical experts by Revenue Synthesis Group and further strengthen the background of the medical and pharmaceutical team of the Group. In addition, the Medical Committee would contribute to the Group by introducing potential investors and investment opportunities which is related to the AIDS medications and therapies.

Thus, the Board is of the view that, with the entering into of the Exclusive Agreement dated 8 July 2013, the establishment of the Medical Committee is in line with the abovementioned strategy of the Group as stated in the 2013 annual report of the Group and is able to broaden the income source and diversify the business risk of the Group in the future which are in the interests of the Company and Shareholders as a whole.

By Order of the Board
Chanceton Financial Group Limited
Wong Kam Wah
Chief executive officer and executive director

Hong Kong, 17 October 2013

As at the date of this announcement, the Company's executive Directors are Ms. Ho Chiu Ha Maisy (Chairman), Mr. Tsang Yan, Mr. Wong Kam Wah, Mr. Lau Ling Tak, Ms. Man Wing Yee Ginny, Mr. Leung Man Kit, and the independent non-executive Directors are Mr. Chiu Chi Kong, Mr. William Robert Majcher and Mr. Yau Yan Ming Raymond.

This announcement, for which the Directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors of the Company, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (i) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and (ii) there are no other matters the omission of which would make any statement in this announcement misleading.

This announcement will remain on the GEM website (www.hkgem.com) and on the "Latest Company Announcements" page for at least 7 days from the date of its posting. This announcement will also be published on the Company's website (www.chanceton.com)